Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease.

Sci Rep · 2025 · PMC12117165 · PMID 40425709

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

5 B, venetoclax-treated mice exhibited a nonsignificant trend toward reduced IFN-γ levels, whereas the reduction was not observed in solvent-treated controls.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.